Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Generated: May 29, 2017
Which patents cover Prevacid, and when can generic versions of Prevacid launch?
Prevacid is a drug marketed by Takeda Pharms Usa, Takeda Pharms Na, and Glaxosmithkline Cons. and is included in six NDAs. There are five patents protecting this drug and two Paragraph IV challenges.| Patents: | 4 |
| Applicants: | 3 |
| NDAs: | 6 |
| Suppliers / Packagers: see list | 9 |
| Bulk Api Vendors: see list | 81 |
| Clinical Trials: see list | 9 |
| Patent Applications: see list | 3,852 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | PREVACID at DailyMed |
| Drug Class | Proton Pump Inhibitor |
| Mechanism of Action | Proton Pump Inhibitors |
| Physiological Effect | Inhibition Gastric Acid Secretion |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | PREVACID | lansoprazole | CAPSULE, DELAYED REL PELLETS;ORAL | 020406-001 | May 10, 1995 | AB | RX | Yes | No | ► Subscribe | ► Subscribe | ||||||||||||||||||
Takeda Pharms Usa | PREVACID | lansoprazole | TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL | 021428-002 | Aug 30, 2002 | RX | Yes | Yes | 6,328,994*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Takeda Pharms Usa | PREVACID | lansoprazole | TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL | 021428-001 | Aug 30, 2002 | RX | Yes | No | 7,399,485*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Takeda Pharms Na | PREVACID | lansoprazole | FOR SUSPENSION, DELAYED RELEASE;ORAL | 021281-002 | May 3, 2001 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Takeda Pharms Usa | PREVACID | lansoprazole | TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL | 021428-002 | Aug 30, 2002 | RX | Yes | Yes | 7,399,485*PED | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Orange Book Patents
Available with subscription
Paragraph IV Activity
Available with subscription
Patent Maintenance
Available with subscription
Non-Orange Book Patents
Available with subscription
International Patents
Available with subscription
Supplementary Protection Certificates
Available with subscription
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
